BD Announces Intent to Separate Biosciences and Diagnostic Solutions Business to Enhance Focus, Drive Growth and Unlock Value
BD (Becton, Dickinson and Company) (NYSE: BDX), a leading global medical technology company, today announced its board of directors has unanimously authorized BD management to pursue a plan to separate BD's Biosciences and Diagnostic Solutions business from the rest of BD to enhance strategic focus and growth-oriented investments and capital allocation for both BD and the separated business and enhance value creation for shareholders.
Becton Dickinson Q1 Earnings: Revenue And EPS Beat, Lowers Outlook, Outlines Intent To Separate Biosciences And Diagnostic Solutions Business
Becton Dickinson plans to spin off its Biosciences and Diagnostic Solutions unit, targeting a fiscal 2026 completion, while updating FY25 revenue guidance.
Becton Dickinson to Split from Bioscience and Diagnostic Solutions Arms
American medical technology (MedTech) company Becton Dickinson (BDX) plans to split from its bioscience and diagnostic solutions arms to become
Becton Dickinson to Separate From Bioscience and Diagnostic Solutions Business
Chief Executive Tom Polen said he believes the separation would help differentiate BD in the medical-technology industry, and allow the company to invest more in innovation and margin growth.
Becton looks to separate biosciences and diagnostic solutions after upbeat quarterly results
Becton Dickinson beat expectations for first-quarter results and said its board has authorized a plan to separate its biosciences and diagnostic solutions unit on Wednesday, as the medical device maker aims to focus on its core business.
Becton Dickinson to break off biosciences, diagnostic solutions
Becton Dickinson said it would focus on medtech and prioritize research, acquisitions and high-growth markets.
Zacks.com on MSN12h
BD Stock Falls in Pre-Market Despite Q1 Earnings Beat, Gross Margin Up
Becton, Dickinson and Company BDX, popularly known as BD, delivered adjusted earnings per share (EPS) of $3.43 in the first ...
BD stock slides amid earnings report, business split update
Becton Dickinson (NYSE:BDX) stock was down 3% in morning trading Thursday, the day after the company released its fiscal Q1 earnings report and confirmed it was splitting the company into two separate ...
MassDevice3d
Activist investors reportedly push BD to sell Life Sciences biz
The Financial Times reports today that an activist investor wants BD (NYSE:BDX) to sell off its Life Sciences business unit.
BD sees FY25 adjusted EPS $14.30-$14.60 vs. previous view $14.25-$14.60
Consensus is $14.35. Sees FY25 revenue $21.7B-$21.9B vs. previous view $21.9B-$22.1B, consensus $21.93B.Maximize Your Portfolio with Data ...
Becton, Dickinson and Company (BDX) Q1 2025 Earnings Call Transcript
At the request of BD, today's call is being recorded and will be available for replay on BD's Investor Relations website, investors.bd.com or by phone at 1-800-839-2486 for domestic calls and area ...
Bdcnetwork.com11h
Top 50 Laboratory Construction Firms for 2024
Whiting-Turner Contracting, Suffolk Construction, Skanska USA, STO Building Group, Truebeck Construction, and Hensel Phelps ...
Soap Central on MSN2d
Ye releases first YZY Womenswear BD-01 Bodysuit: All you need to know
Kanye West, also known as ‘Ye,’ is starting his women’s fashion venture by launching the YZY Womenswear line. The American ...